Advanced Therapies for Brain Cancer
Building the evidence, expertise and capability needed to advance cell and gene therapies for childhood and adult brain cancer.
Laying the Foundations for Cell and Gene Therapies in Brain Cancer
In 2026, Advanced Therapies for Brain Cancer (ATBC) received $5 million over 5 years with a further $4 million over 4 years subject to exceptional progress.
A total investment of up to $9 million over 9 years, thanks to funding from the Future Health Research and Innovation (FHRI) Fund, the McCusker Charitable Trust and Stan Perron Charitable Foundation as part of the WA Comprehensive Kids Cancer Centre to support a program which will be administered by the Cancer Research Trust.
ATBC is a four-pillar programme uniting five Western Australian institutions: Cell & Tissue Therapies WA (CTTWA) at East Metropolitan Health Service, Western Australia’s only public hospital-based TGA-licensed advanced therapy manufacturing facility. The Kids Research Institute Australia, home to Australia’s only juvenile-age preclinical brain cancer platform. The University of Western Australia, through the Australian Centre for RNA Therapeutics in Cancer. Perth Children’s Hospital, delivering the paediatric Phase I clinical trial. Royal Perth Hospital, delivering the parallel adult Phase I clinical trial.
WA Brain Cancer Translation Pipeline for Adults and Children
Childhood brain tumours remain the leading cause of cancer-related death in children. For aggressive cancers such as DMG/DIPG, treatment options remain limited and survival outcomes have changed little in decades.
CAR-T cell therapy has emerged as one of the most promising new treatment approaches in paediatric neuro-oncology with international CAR-T preclinical studies generating meaningful responses in some patients.
The programme spans discovery, manufacturing, and clinical translation. It will develop CAR T-cells, CAR NK cells, mRNA, TIL, and tumour-microenvironment conditioning strategies, tested in Australia’s only juvenile-age and adult brain cancer models.
By building this translational pipeline within WA, from laboratory to GMP manufacturing to clinical delivery, the programme establishes durable WA capability that will serve brain cancer patients and the wider WA cancer research community well beyond the five-year grant period.
2,098
Number of Australians diagnosed with brain cancer each year.
The Second
Most commonly diagnosed cancer in children.
“There are still many unanswered questions when it comes to advanced therapies for brain cancer, and answering them takes time. What makes this program special is the opportunity to bring together people with different expertise and work towards a common goal over the long term.
The sustained funding gives us the continuity to build strong collaborations, test and refine new ideas, and generate the kind of evidence that’s needed to understand which approaches have the greatest potential to improve outcomes for patients.”
Associate Professor Zlatibor Kovacevic
Program Lead
ATBC Team Leads
Professor Nick Gottardo
Clinical Lead
Enabled Through Funding From
Future Health Research and Innovation Fund
The McCusker Charitable Foundation
Stan Perron Charitable Foundation as part of the WA Comprehensive Kids Cancer Centre